CBFP
TRAW icon

Cedar Brook Financial Partners’s Traws Pharma TRAW Stock Holding History

Cedar Brook Financial Partners’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-56
Closed -$6K – 296
2020
Q1 		$6K Buy
+56
New +$8.79K ﹤0.01% 248

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HWA
Hillcrest Wealth Advisors Hazlet, New Jersey $279M AUM 21.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SAMH
Shanda Asset Management Holdings Tortola,, British Virgin Islands $1.85B AUM 36.09% 1-Year Est. Return
QP
Quilter Plc London, United Kingdom $5.7B AUM 21.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cedar Brook Financial Partners's TRAW Position: Q2 2020 in Review

Cedar Brook Financial Partners sold out of Traws Pharma (TRAW) in Q2 2020, closing a stake of 56 shares — an estimated $6K sold.

Cedar Brook Financial Partners first reported a position in TRAW in Q1 2020 and held it in 1 quarter. The position peaked at $6K in Q1 2020. 29 funds tracked by Wall St. Rank hold TRAW as of Q2 2020.

  • Cedar Brook Financial Partners reported no remaining Traws Pharma position as of Q2 2020 after selling out during the quarter.
  • Cedar Brook Financial Partners sold 56 Traws Pharma shares in Q2 2020, an estimated $6K.
  • Cedar Brook Financial Partners first reported a position in Traws Pharma in Q1 2020 and held it in 1 quarter.
  • Cedar Brook Financial Partners's Traws Pharma position peaked at $6K in Q1 2020.
  • 29 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2020.

Based on Cedar Brook Financial Partners's 13F filing for Q2 2020, filed 5 Aug 2020.